CD8A and lymphoma: We have previously shown that we were able to generate via IV injection of CD8- or CD3- targeted LVs in humanized or xenograft mouse models, human CAR T cells in vivo that were able to eliminate healthy B cells or lymphoma B cells [27, 28, 30, 33].